These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 38252038

  • 1. Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence.
    Martin-Loeches I, Bruno CJ, DeRyke CA.
    Future Microbiol; 2024; 19(6):465-480. PubMed ID: 38252038
    [Abstract] [Full Text] [Related]

  • 2. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [Abstract] [Full Text] [Related]

  • 3. Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia.
    Martin-Loeches I, Bisanti A, Diaz E, Rodriguez A.
    Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1177-1185. PubMed ID: 32662691
    [Abstract] [Full Text] [Related]

  • 4. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
    Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, Menichetti F, Mastroianni CM, Tumbarello M, Grossi P, Artioli S, Carannante N, Cipriani L, Coletto D, Russo A, Digaetano M, Losito AR, Peghin M, Capone A, Nicolè S, Vena A, CEFTABUSE Study Group.
    Int J Antimicrob Agents; 2019 Apr; 53(4):408-415. PubMed ID: 30415002
    [Abstract] [Full Text] [Related]

  • 5. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
    Meschiari M, Asquier-Khati A, Tiseo G, Luque-Paz D, Murri R, Boutoille D, Falcone M, Mussini C, Tattevin P, Italian Society of Infectious and Tropical Diseases (SIMIT), and the French Society of Infectious Diseases (SPILF).
    Int J Antimicrob Agents; 2024 Jul; 64(1):107186. PubMed ID: 38688353
    [Abstract] [Full Text] [Related]

  • 6. Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
    Kollef MH, Timsit JF, Martin-Loeches I, Wunderink RG, Huntington JA, Jensen EH, Yu B, Bruno CJ.
    Crit Care; 2022 Dec 01; 26(1):373. PubMed ID: 36457059
    [Abstract] [Full Text] [Related]

  • 7. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
    Kollef MH, Nováček M, Kivistik Ü, Réa-Neto Á, Shime N, Martin-Loeches I, Timsit JF, Wunderink RG, Bruno CJ, Huntington JA, Lin G, Yu B, Butterton JR, Rhee EG.
    Lancet Infect Dis; 2019 Dec 01; 19(12):1299-1311. PubMed ID: 31563344
    [Abstract] [Full Text] [Related]

  • 8. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
    Sucher AJ, Chahine EB, Cogan P, Fete M.
    Ann Pharmacother; 2015 Sep 01; 49(9):1046-56. PubMed ID: 26160970
    [Abstract] [Full Text] [Related]

  • 9. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
    Timsit JF, Huntington JA, Wunderink RG, Shime N, Kollef MH, Kivistik Ü, Nováček M, Réa-Neto Á, Martin-Loeches I, Yu B, Jensen EH, Butterton JR, Wolf DJ, Rhee EG, Bruno CJ.
    Crit Care; 2021 Aug 11; 25(1):290. PubMed ID: 34380538
    [Abstract] [Full Text] [Related]

  • 10. Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
    Bassetti M, Righi E.
    Future Microbiol; 2015 Aug 11; 10(2):151-60. PubMed ID: 25689527
    [Abstract] [Full Text] [Related]

  • 11. Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.
    Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Simon SP, Bhatia S, Melvin SM, Steed ME, Finch NA, Morrisette T, Estrada SJ, Rosenberg JR, Davis SL, Rybak MJ.
    Antimicrob Agents Chemother; 2020 Mar 24; 64(4):. PubMed ID: 31932379
    [Abstract] [Full Text] [Related]

  • 12. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK.
    Int J Antimicrob Agents; 2018 Feb 24; 51(2):181-189. PubMed ID: 28993143
    [Abstract] [Full Text] [Related]

  • 13. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC, Fiorenza MA, Estrada SJ.
    Pharmacotherapy; 2015 Jul 24; 35(7):701-15. PubMed ID: 26133315
    [Abstract] [Full Text] [Related]

  • 14. Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
    Paterson DL, Bassetti M, Motyl M, Johnson MG, Castanheira M, Jensen EH, Huntington JA, Yu B, Wolf DJ, Bruno CJ.
    J Antimicrob Chemother; 2022 Aug 25; 77(9):2522-2531. PubMed ID: 35781341
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.
    Carvalhaes CG, Castanheira M, Sader HS, Flamm RK, Shortridge D.
    Diagn Microbiol Infect Dis; 2019 May 25; 94(1):93-102. PubMed ID: 30642717
    [Abstract] [Full Text] [Related]

  • 16. Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
    Feng HP, Patel YT, Zhang Z, Fiedler-Kelly J, Bruno CJ, Rhee EG, De Anda C, Gao W.
    J Clin Pharmacol; 2023 Feb 25; 63(2):166-171. PubMed ID: 36046982
    [Abstract] [Full Text] [Related]

  • 17. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS, Farrell DJ, Flamm RK, Jones RN.
    J Infect; 2014 Sep 25; 69(3):266-77. PubMed ID: 24780763
    [Abstract] [Full Text] [Related]

  • 18. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
    Johnson MG, Bruno C, Castanheira M, Yu B, Huntington JA, Carmelitano P, Rhee EG, De Anda C, Motyl M.
    Int J Antimicrob Agents; 2021 Mar 25; 57(3):106278. PubMed ID: 33434676
    [Abstract] [Full Text] [Related]

  • 19. Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Gao W, Patel YT, Zhang Z, Johnson MG, Fiedler-Kelly J, Bruno CJ, Rhee EG, Anda C, Feng HP.
    J Clin Pharmacol; 2023 Mar 25; 63(3):352-357. PubMed ID: 36201105
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β-lactamase inhibitor combination.
    Katzenstein TL, Faurholt-Jepsen D, Qvist T, Jensen PØ, Pressler T, Johansen HK, Kolpen M.
    APMIS; 2023 Aug 25; 131(8):419-425. PubMed ID: 37294911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.